A Preliminary Analysis of Circulating Tumor Microemboli from Breast Cancer Patients during Follow-Up Visits
Background: Most breast cancer-related deaths are caused by distant metastases and drug resistance. It is important to find appropriate biomarkers to monitor the disease and to predict patient responses after treatment early and accurately. Many studies have found that clustered circulating tumor ce...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-09-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/31/9/421 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850261223453491200 |
|---|---|
| author | Hung-Chih Lai Hsing-Hua Huang Yun-Jie Hao Hsin-Ling Lee Chiao-Chan Wang Thai-Yen Ling Jen-Kuei Wu Fan-Gang Tseng |
| author_facet | Hung-Chih Lai Hsing-Hua Huang Yun-Jie Hao Hsin-Ling Lee Chiao-Chan Wang Thai-Yen Ling Jen-Kuei Wu Fan-Gang Tseng |
| author_sort | Hung-Chih Lai |
| collection | DOAJ |
| description | Background: Most breast cancer-related deaths are caused by distant metastases and drug resistance. It is important to find appropriate biomarkers to monitor the disease and to predict patient responses after treatment early and accurately. Many studies have found that clustered circulating tumor cells, with more correlations with metastatic cancer and poor survival of patients than individual ones, are promising biomarkers. Methods: Eighty samples from eleven patients with breast cancer during follow-up visits were examined. By using a microfluidic chip and imaging system, the number of circulating tumor cells and microemboli (CTC/CTM) were counted to assess the distribution in stratified patients and the potential in predicting the disease condition of patients after treatments during follow-up visits. Specific components and subtypes of CTM were also preliminarily investigated. Results: Compared to CTC, CTM displayed a distinguishable distribution in stratified patients, having a better AUC value, in predicting the disease progression of breast cancer patients during follow-up visits in this study. Four subtypes were categorized from the identified CTM by considering different components. In combination with CEA and CA153, enumerated CTC and CTM from individual patients were applied to monitor the disease condition and patient response to the therapy during follow-up visits. Conclusions: The CTM and its subtypes are promising biomarkers and valuable tools for studying cancer metastasis and longitudinally monitoring cancer patients during follow-up visits. |
| format | Article |
| id | doaj-art-7b9c3edd8a1f444981979fcd93b63c2a |
| institution | OA Journals |
| issn | 1198-0052 1718-7729 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj-art-7b9c3edd8a1f444981979fcd93b63c2a2025-08-20T01:55:28ZengMDPI AGCurrent Oncology1198-00521718-77292024-09-013195677569310.3390/curroncol31090421A Preliminary Analysis of Circulating Tumor Microemboli from Breast Cancer Patients during Follow-Up VisitsHung-Chih Lai0Hsing-Hua Huang1Yun-Jie Hao2Hsin-Ling Lee3Chiao-Chan Wang4Thai-Yen Ling5Jen-Kuei Wu6Fan-Gang Tseng7Division of Hematology and Oncology, Department of Internal Medicine, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei 11101, TaiwanDivision of Breast Surgery Clinic, En Chu Kong Hospital, No. 258, Zhongshan Rd., Sanxia Dist., New Taipei City 237, TaiwanDepartment of Engineering and System Science, National Tsing Hua University, No. 101, Sec. 2, Kuang-Fu Rd., Hsinchu 30013, TaiwanDepartment of Engineering and System Science, National Tsing Hua University, No. 101, Sec. 2, Kuang-Fu Rd., Hsinchu 30013, TaiwanDepartment of Engineering and System Science, National Tsing Hua University, No. 101, Sec. 2, Kuang-Fu Rd., Hsinchu 30013, TaiwanGraduate Institute of Pharmacology, National Taiwan University, No. 33, Linsen S. Rd., Zhongzheng Dist., Taipei City 100025, TaiwanDepartment of Engineering and System Science, National Tsing Hua University, No. 101, Sec. 2, Kuang-Fu Rd., Hsinchu 30013, TaiwanDepartment of Engineering and System Science, National Tsing Hua University, No. 101, Sec. 2, Kuang-Fu Rd., Hsinchu 30013, TaiwanBackground: Most breast cancer-related deaths are caused by distant metastases and drug resistance. It is important to find appropriate biomarkers to monitor the disease and to predict patient responses after treatment early and accurately. Many studies have found that clustered circulating tumor cells, with more correlations with metastatic cancer and poor survival of patients than individual ones, are promising biomarkers. Methods: Eighty samples from eleven patients with breast cancer during follow-up visits were examined. By using a microfluidic chip and imaging system, the number of circulating tumor cells and microemboli (CTC/CTM) were counted to assess the distribution in stratified patients and the potential in predicting the disease condition of patients after treatments during follow-up visits. Specific components and subtypes of CTM were also preliminarily investigated. Results: Compared to CTC, CTM displayed a distinguishable distribution in stratified patients, having a better AUC value, in predicting the disease progression of breast cancer patients during follow-up visits in this study. Four subtypes were categorized from the identified CTM by considering different components. In combination with CEA and CA153, enumerated CTC and CTM from individual patients were applied to monitor the disease condition and patient response to the therapy during follow-up visits. Conclusions: The CTM and its subtypes are promising biomarkers and valuable tools for studying cancer metastasis and longitudinally monitoring cancer patients during follow-up visits.https://www.mdpi.com/1718-7729/31/9/421breast cancercirculating tumor cells (CTC)circulating tumor microemboli (CTM)liquid biopsy biomarkertumor immune microenvironment |
| spellingShingle | Hung-Chih Lai Hsing-Hua Huang Yun-Jie Hao Hsin-Ling Lee Chiao-Chan Wang Thai-Yen Ling Jen-Kuei Wu Fan-Gang Tseng A Preliminary Analysis of Circulating Tumor Microemboli from Breast Cancer Patients during Follow-Up Visits Current Oncology breast cancer circulating tumor cells (CTC) circulating tumor microemboli (CTM) liquid biopsy biomarker tumor immune microenvironment |
| title | A Preliminary Analysis of Circulating Tumor Microemboli from Breast Cancer Patients during Follow-Up Visits |
| title_full | A Preliminary Analysis of Circulating Tumor Microemboli from Breast Cancer Patients during Follow-Up Visits |
| title_fullStr | A Preliminary Analysis of Circulating Tumor Microemboli from Breast Cancer Patients during Follow-Up Visits |
| title_full_unstemmed | A Preliminary Analysis of Circulating Tumor Microemboli from Breast Cancer Patients during Follow-Up Visits |
| title_short | A Preliminary Analysis of Circulating Tumor Microemboli from Breast Cancer Patients during Follow-Up Visits |
| title_sort | preliminary analysis of circulating tumor microemboli from breast cancer patients during follow up visits |
| topic | breast cancer circulating tumor cells (CTC) circulating tumor microemboli (CTM) liquid biopsy biomarker tumor immune microenvironment |
| url | https://www.mdpi.com/1718-7729/31/9/421 |
| work_keys_str_mv | AT hungchihlai apreliminaryanalysisofcirculatingtumormicroembolifrombreastcancerpatientsduringfollowupvisits AT hsinghuahuang apreliminaryanalysisofcirculatingtumormicroembolifrombreastcancerpatientsduringfollowupvisits AT yunjiehao apreliminaryanalysisofcirculatingtumormicroembolifrombreastcancerpatientsduringfollowupvisits AT hsinlinglee apreliminaryanalysisofcirculatingtumormicroembolifrombreastcancerpatientsduringfollowupvisits AT chiaochanwang apreliminaryanalysisofcirculatingtumormicroembolifrombreastcancerpatientsduringfollowupvisits AT thaiyenling apreliminaryanalysisofcirculatingtumormicroembolifrombreastcancerpatientsduringfollowupvisits AT jenkueiwu apreliminaryanalysisofcirculatingtumormicroembolifrombreastcancerpatientsduringfollowupvisits AT fangangtseng apreliminaryanalysisofcirculatingtumormicroembolifrombreastcancerpatientsduringfollowupvisits AT hungchihlai preliminaryanalysisofcirculatingtumormicroembolifrombreastcancerpatientsduringfollowupvisits AT hsinghuahuang preliminaryanalysisofcirculatingtumormicroembolifrombreastcancerpatientsduringfollowupvisits AT yunjiehao preliminaryanalysisofcirculatingtumormicroembolifrombreastcancerpatientsduringfollowupvisits AT hsinlinglee preliminaryanalysisofcirculatingtumormicroembolifrombreastcancerpatientsduringfollowupvisits AT chiaochanwang preliminaryanalysisofcirculatingtumormicroembolifrombreastcancerpatientsduringfollowupvisits AT thaiyenling preliminaryanalysisofcirculatingtumormicroembolifrombreastcancerpatientsduringfollowupvisits AT jenkueiwu preliminaryanalysisofcirculatingtumormicroembolifrombreastcancerpatientsduringfollowupvisits AT fangangtseng preliminaryanalysisofcirculatingtumormicroembolifrombreastcancerpatientsduringfollowupvisits |